Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | May 21, 2026 | May 22, 2026 |
| Rallybio CorpRLYB · Entity 6838 | Director | May 13, 2025 | May 15, 2025 |
| uniQure N.V.QURE · Entity 4162 | Director | June 13, 2024 | June 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.63 · Expires 2036-05-21 | Direct | 6,090 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 6,090 · Balance 6,090 F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Rallybio Corp
Report date May 13, 2025 · Filed May 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2035-05-13 | Direct | 28,500 |
Reported balance
After 2025-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-13 · Grant · Acquired 28,500 · Balance 28,500 F1: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.
uniQure N.V.
Report date June 13, 2024 · Filed June 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,203 |
Reported balance
After 2024-06-13 transaction · row 1
1 source rowRow 1 · 2024-06-13 · Sale · Disposed 2,220 · Balance 20,203 F1: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date September 26, 2019 · Filed September 30, 2019
Section 16 reporting ended · disclosed 2019-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 678,149 |
Ending reported balance
After 2019-09-26 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2019-09-26 · Exercise / conversion · Acquired 1,711,079 · Balance 1,711,079 Row 2 · 2019-09-26 · Tax withholding · Disposed 1,113,492 · Balance 597,587 Row 3 · 2019-09-26 · Exercise / conversion · Acquired 145,303 · Balance 742,890 Row 4 · 2019-09-26 · Tax withholding · Disposed 95,156 · Balance 647,734 Row 5 · 2019-09-26 · Exercise / conversion · Acquired 205,479 · Balance 853,213 Row 6 · 2019-09-26 · Tax withholding · Disposed 175,064 · Balance 678,149 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2025-12-15 | Direct | 0 |
Reported balance
After 2019-09-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-09-26 · Exercise / conversion · Disposed 1,711,079 · Balance 0 F1: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2026-02-16 | Direct | 13,209 |
Reported balance
After 2019-09-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-09-26 · Exercise / conversion · Disposed 145,303 · Balance 13,209 F2: The shares vest as follows: 1/4th of the shares vest one year after January 4, 2016;1/48th of the shares vest monthly thereafter over the next three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-06-04 | Direct | 102,740 |
Reported balance
After 2019-09-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-09-26 · Exercise / conversion · Disposed 205,479 · Balance 102,740 F3: The shares vest as follows: 1/4th of the shares vest one year after January 3, 2017;1/48th of the shares vest monthly thereafter over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years.
F2: The shares vest as follows: 1/4th of the shares vest one year after January 4, 2016;1/48th of the shares vest monthly thereafter over the next three years.
F3: The shares vest as follows: 1/4th of the shares vest one year after January 3, 2017;1/48th of the shares vest monthly thereafter over the next three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,090 | $0.00 Strike: $89.63 | $0.00 |
DisclosureSEC source: 0001692444-26-000010 · ownership.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,090 Underlying: Common Stock · 6,090 shares Expires 2036-05-21 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 599 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001692444-26-000008 · ownership.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 599 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on April 6, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 599 | $85.47 | $51,196.53 |
DisclosureSEC source: 0001692444-26-000008 · ownership.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 599 | $8.44 | $5,055.56 |
DisclosureSEC source: 0001692444-26-000008 · ownership.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 599 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001692444-26-000006 · ownership.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 599 Underlying: Common Stock · 599 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on April 6, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 599 | $80.11 | $47,985.89 |
DisclosureSEC source: 0001692444-26-000006 · ownership.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:26 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 599 | $8.44 | $5,055.56 |
DisclosureSEC source: 0001692444-26-000006 · ownership.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 22:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,594 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001692444-26-000003 · ownership.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,198 Underlying: Common Stock · 27,594 shares Expires 2032-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on April 6, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 22:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 27,594 | $78.05 | $2,153,711.70 |
DisclosureSEC source: 0001692444-26-000003 · ownership.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 22:00 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 27,594 | $8.44 | $232,893.36 |
DisclosureSEC source: 0001692444-26-000003 · ownership.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. Read SEC document |
| May 22, 2025 Filed May 22, 2025 20:43 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0000950170-25-076410 · ownership.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:05 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001739410-25-000082 · wk-form4_1747343116.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-05-13 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:24 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,220 | $5.14 | $11,410.80 |
DisclosureSEC source: 0000904454-24-000369 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,203 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:59 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065545 · ownership.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:04 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001739410-24-000090 · wk-form4_1715979851.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-15 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:16 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0000899243-23-018866 · doc4.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-09-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:30 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,275 | $18.99 | $43,202.25 |
DisclosureSEC source: 0000904454-23-000402 · edgar.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,423 F3 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F3 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.95 to $19.00. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:30 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,060 | $0.00 Strike: $20.18 | $0.00 |
DisclosureSEC source: 0000904454-23-000402 · edgar.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,060 Underlying: Ordinary Shares · 17,060 shares Expires 2033-06-13 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:30 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000402 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,698 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:24 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 15,490 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0000899243-23-013402 · doc4.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,490 Underlying: Common Stock · 15,490 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 17, 2024 or the date of the Company's 2024 Annual Meeting of Stockholders. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:16 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 384 | $19.97 | $7,668.48 |
DisclosureSEC source: 0000899243-23-006589 · doc4.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,998 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.92 to $20.01. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 20:57 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000904454-23-000031 · edgar.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Ordinary Shares · 6,000 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 20:57 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6,000 | $22.59 | $135,540.00 |
DisclosureSEC source: 0000904454-23-000031 · edgar.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,382 F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 20:57 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 6,000 | $5.37 | $32,220.00 |
DisclosureSEC source: 0000904454-23-000031 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000633 · edgar.xml · derivative · entry 6 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,800 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Stock Option exercise price was EUR 10.10 per share or $10.69, as converted, based on the exchange rate at on December 13, 2022 of EUR 1 to $1.058. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: The Stock Option was granted on June 6, 2013 and vested 25% after one year, with the remainder vesting in weekly installments over a two year period ending on June 10, 2016. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,800 | $23.43 | $89,034.00 |
DisclosureSEC source: 0000904454-22-000633 · edgar.xml · nonDerivative · entry 4 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,382 F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 3,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-22-000633 · edgar.xml · nonDerivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The Stock Option exercise price was EUR 10.10 per share or $10.69, as converted, based on the exchange rate at on December 13, 2022 of EUR 1 to $1.058. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000904454-22-000633 · edgar.xml · derivative · entry 5 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 3,000 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,000 | $23.45 | $70,350.00 |
DisclosureSEC source: 0000904454-22-000633 · edgar.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,382 F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 22:09 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 3,000 | $5.37 | $16,110.00 |
DisclosureSEC source: 0000904454-22-000633 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:14 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000601 · edgar.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Underlying: Ordinary Shares · 6,200 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Stock Option exercise price was EUR 10.10 per share or $10.46, as converted, based on the exchange rate at exercise of EUR 1 to $1.036. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · derivative.exercise_date: The Stock Option was granted on June 6, 2013 and vested 25% after one year, with the remainder vesting in weekly installments over a two year period ending on June 10, 2016. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:14 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 6,200 | $25.38 | $157,356.00 |
DisclosureSEC source: 0000904454-22-000601 · edgar.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,382 F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.33 to $25.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:14 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionOrdinary Shares | 6,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-22-000601 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The Stock Option exercise price was EUR 10.10 per share or $10.46, as converted, based on the exchange rate at exercise of EUR 1 to $1.036. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:31 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,810 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000904454-22-000356 · edgar.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Ordinary Shares · 17,810 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:31 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 9,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000356 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,382 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| May 24, 2022 Filed May 27, 2022 00:11 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 13,440 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0000899243-22-019834 · doc4.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 13,440 shares Expires 2032-05-24 F1 · derivative.exercise_date: The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 24, 2023 or the date of the Company's 2023 Annual Meeting of Stockholders. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:26 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 596 | $16.87 | $10,054.52 |
DisclosureSEC source: 0000904454-22-000211 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,302 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.82 to $16.88. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:15 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 2,645 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0000904454-22-000189 · edgar.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645 Underlying: Ordinary Shares · 2,645 shares Expires 2032-02-24 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:15 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 1,534 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000189 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,898 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:37 UTC | Rallybio Corp RLYB · Entity 6838 | GrantOption (Right to Buy) · Derivative | 5,369 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0000899243-22-001056 · doc4.xml · derivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires 2032-01-03 F1 · derivative.exercise_date: The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:19 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 504 | $37.60 | $18,950.40 |
DisclosureSEC source: 0000904454-21-000293 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,364 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.76 to $37.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:23 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 4,107 | $0.00 Strike: $37.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000261 · edgar.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Underlying: Ordinary Shares · 4,107 shares Expires 2031-02-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:23 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000261 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,868 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:49 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 3,620 | $0.00 Strike: $51.81 | $0.00 |
DisclosureSEC source: 0000904454-20-000259 · edgar.xml · derivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,620 Underlying: Ordinary Shares · 3,620 shares Expires 2030-02-27 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:49 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000259 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,486 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 05, 2020 Filed Feb 5, 2020 18:19 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 822 | $61.53 | $50,577.66 |
DisclosureSEC source: 0000904454-20-000154 · edgar.xml · nonDerivative · entry 2 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,423 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.13 to $61.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2020 Filed Feb 5, 2020 18:19 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,300 | $60.58 | $78,754.00 |
DisclosureSEC source: 0000904454-20-000154 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,245 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.10 to $60.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2020 Filed Jan 31, 2020 02:15 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 807 | $62.19 | $50,187.33 |
DisclosureSEC source: 0000904454-20-000116 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,545 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.46 to $62.20. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 18:48 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 3,000 | $72.18 | $216,540.00 |
DisclosureSEC source: 0000904454-20-000011 · edgar.xml · nonDerivative · entry 1 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,352 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.79 to $72.62. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:06 UTC | uniQure N.V. QURE · Entity 4162 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000904454-19-000749 · edgar.xml · derivative · entry 3 Soteropoulos Paula · CIK 0001692444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 2,000 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option vested on January 27, 2018, the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.